## Index

ACP. See advance care planning

activity-based interventions, for dementia
exercise therapy, 216–17
individual activity programmes, 217

acute medical settings, residence capacity assessment in, 308–9, 310

AD. See Alzheimer’s disease

Addenbrooke’s Cognitive Examination, 41

ADL. See adrenoleukodystrophy

ADNI study. See Alzheimer’s Disease Neuroimaging Initiative study

adrenoleukodystrophy (ADL), 67

adrenomyeloneuropathy (AMN), 67

Adults with Incapacity (Scotland) Act 2000, 279, 281

advance care planning (ACP), 236

agitation, pain and, 233

agomelatine, 246

AIDS dementia complex, 57–8

alcohol misuse, 92, 101–2

acute presentations of, 96–7

assessment of, 93–4

brain damage related to, 99

challenges to recovery from, 95

drug interactions with, 98–9

drug misuse with, 108

epidemiology of, 16, 92–3

family and carer support for, 94–5

legal and ethical aspects of, 95–6

multi-agency working for, 100–1

physical presentations of, 97–8

psychosocial interventions for, 94, 95

screening for, 94

self-harm and suicide associated with, 98

toxicity associated with, 62

Alcohol Use Disorders Identification Test (AUDIT), 94

alcohol withdrawal syndrome, 96–7

alcohol-related brain damage (ARBD), 99

alcohol-related dementia, 45 allocation, for home assessment, 130–1

ALS. See amyotrophic lateral sclerosis

aluminium toxicity, 60

Alzheimer’s disease (AD). See also preclinical AD diagnostic criteria for, 167, 174, 176

driving with, 141

epidemiology of, 5, 9–10

familial, 50

neuroimaging in diagnosis of, 173–4, 176, 186–7

CT, 174

future techniques for, 178

MRI, 174–7

PET, 177–8

SPECT, 177

risk factors for, 9–10

VaD/VCI compared with, 30–1

VaD/VCI mixed with, 24–5, 6

young-onset, 43

Alzheimer’s Disease Neuroimaging Initiative (ADNI) study, 166

aMCI. See amnestic mild cognitive impairment

AMCP. See Approved Mental Capacity Professional

AMN. See adrenomyeloneuropathy

amnestic mild cognitive impairment (aMCI), 161, 162

amphetamine, misuse of, 106, 108

amyloid-β, in AD at different disease stages, 166

measurement of, 164–5, 178

pathophysiology, 162–3

predictive accuracy of, 165–6

amyotrophic lateral sclerosis (ALS), 52

analytical epidemiology, 5–6

animal-assisted therapy, 216

anoxic brain injury, 63

antibiotics, in advanced dementia, 233–4

anticholinergic medications, toxicity associated with, 60–1

antidepressants for depression in PD, 116–18

for late-life depression age-related physiological changes affecting, 244

combination and augmentation therapy, 246–7

dementia with, 249

monotherapy, 245

relapse prevention, 247

response time for, 246

mania induced by, 79

toxicity associated with, 60–1

for young-onset dementia, 47

antispsychotic agents for bipolar disorder, 86

for delirium, 261–2

DLB with sensitivity to, 45

for late-life depression, 246–7

for PD psychosis, 121

toxicity associated with, 60

for young-onset dementia, 47
anxiety-related disorders
bipolar disorder comorbidity
with, 83
epidemiology of, 15
in PD, 119–20
apathy, in PD, ...
CBT. See cognitive-behavioural
therapy
CC v KK and STCC [2012],
309–11
Index 331
<table>
<thead>
<tr>
<th>Index</th>
<th>332</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cerebral amyloid (congophilic) angiopathy (CAA), 29, 53</td>
<td>CNS vasculitis, 70</td>
</tr>
<tr>
<td>Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), 28–9, 53–4</td>
<td>Cocaine misuse, 106, 107–8</td>
</tr>
<tr>
<td>Cerebral hypoxia, 63</td>
<td>Coeliac disease, 70</td>
</tr>
<tr>
<td>Cerebral lipidoses – adult variant, 68</td>
<td>Cognition, substance misuse impacts on, 111</td>
</tr>
<tr>
<td>Cerebral toxocariasis, 57</td>
<td>Cognitive Function and Ageing Studies (CFAS), 8–9, 29</td>
</tr>
<tr>
<td>Cerebral tumours, 68–9</td>
<td>Cognitive impairment. See also dementia</td>
</tr>
<tr>
<td>Cerebrospinal fluid (CSF), AD biomarkers in, 164–5, 169</td>
<td>Alcohol misuse and, 95–6</td>
</tr>
<tr>
<td>At different disease stages, 166</td>
<td>Bipolar disorder comorbidity with, 83</td>
</tr>
<tr>
<td>Further questions for, 170</td>
<td>Depression causing, 250</td>
</tr>
<tr>
<td>Limitations of, 168</td>
<td>In PD, 45, 121–3</td>
</tr>
<tr>
<td>Predictive accuracy of, 165–6</td>
<td>Cognitive interventions, 217–18</td>
</tr>
<tr>
<td>Cerebrovascular disease. See vascular dementia/vascular cognitive impairment</td>
<td>Cognitive reserve, 162–3</td>
</tr>
<tr>
<td>CFAS. See Cognitive Function and Ageing Studies</td>
<td>Cognitive testing. See neuropsychological testing</td>
</tr>
<tr>
<td>ChEIs. See cholinesterase inhibitors</td>
<td>Cognitive-behavioural therapy (CBT) for bipolar disorder, 87</td>
</tr>
<tr>
<td>‘Cheshire West’ judgment, 294–6</td>
<td>For late-life depression, 247–8</td>
</tr>
<tr>
<td>Residency capacity and, 308</td>
<td>Cognitive-friendly services for delirium</td>
</tr>
<tr>
<td>Chronic kidney disease, lithium use and, 85</td>
<td>Definition of, 256–7</td>
</tr>
<tr>
<td>Chronic subdural haematoma, 64</td>
<td>Discharge planning and post-hospitalization management, 262</td>
</tr>
<tr>
<td>Citalopram, for late-life depression, 245, 246–7</td>
<td>Experience, education and action in, 257–8</td>
</tr>
<tr>
<td>Civil detention, 282</td>
<td>Improved detection in, 260</td>
</tr>
<tr>
<td>Clinician role in, 282</td>
<td>Key elements for improved care, 262, 263</td>
</tr>
<tr>
<td>Discharge from, 288</td>
<td>Multicomponent non-pharmacological management, 260–1</td>
</tr>
<tr>
<td>Other routes to, 290</td>
<td>Pharmacological management, 261–2</td>
</tr>
<tr>
<td>RC/RMO role in, 288</td>
<td>Primary care practitioners role in, 260</td>
</tr>
<tr>
<td>Tribunal role in, 288–90</td>
<td>Risk factor minimization and prevention in, 259–60</td>
</tr>
<tr>
<td>Emergency, 283, 284–5</td>
<td>Cohort studies, 8</td>
</tr>
<tr>
<td>For mental disorder, 282</td>
<td>Collaborative care, for late-life depression, 247</td>
</tr>
<tr>
<td>Short-term and longer-term detention, 283–6</td>
<td>Community engagement, in dementia care, 205–6</td>
</tr>
<tr>
<td>Statutory criteria for, 282, 284–5</td>
<td>Community reinforcement approach (CRA), 101</td>
</tr>
<tr>
<td>CJD. See Creutzfeldt-Jakob disease</td>
<td>Community treatment orders (CTOs), 281</td>
</tr>
<tr>
<td>Clozapine, 121</td>
<td>Compulsory mental health treatment, 279–82, 286, 289</td>
</tr>
<tr>
<td>Without consent, 286–7</td>
<td>Second opinion safeguards in, 287</td>
</tr>
<tr>
<td>Urgent treatment, 287–8</td>
<td>Computerized tomography (CT) AD, 174</td>
</tr>
<tr>
<td>Other neuroimaging techniques compared with, 175</td>
<td>VaD/VCI, 26, 28–9, 179</td>
</tr>
<tr>
<td>Confidentiality, driving with dementia and, 142, 144</td>
<td>Congophilic angiopathy, 29, 53</td>
</tr>
<tr>
<td>Consent capacity for, 306–7</td>
<td>For home assessment, 131</td>
</tr>
<tr>
<td>Treatment without, 286–7</td>
<td>Consent to treatment provisions, 286–8, 289</td>
</tr>
<tr>
<td>Constipation, in advanced dementia, 231</td>
<td>Constitutive account, 320</td>
</tr>
<tr>
<td>Contingent account, 320</td>
<td>Coroners and Justice Act 2009, 298–9</td>
</tr>
<tr>
<td>Cortical disconnection syndrome, 53</td>
<td>Cortical disconnection, 214</td>
</tr>
<tr>
<td>Corticobasal degeneration, 51</td>
<td>Co-working, in dementia care, 262, 263</td>
</tr>
<tr>
<td>Creatine and, 184, 187</td>
<td>Depression causing, 250</td>
</tr>
<tr>
<td>Cross-sectional surveys, 7</td>
<td>In PD, 45, 121–3</td>
</tr>
<tr>
<td>CSF. See cerebrospinal fluid</td>
<td>Cognitive-behavioural therapy (CBT) for bipolar disorder, 87</td>
</tr>
<tr>
<td>Cognitive-friendly services for delirium</td>
<td>Definition of, 256–7</td>
</tr>
<tr>
<td>Discharge planning and post-hospitalization management, 262</td>
<td>Experience, education and action in, 257–8</td>
</tr>
<tr>
<td>Improved detection in, 260</td>
<td>Key elements for improved care, 262, 263</td>
</tr>
<tr>
<td>Multicomponent non-pharmacological management, 260–1</td>
<td>Pharmacological management, 261–2</td>
</tr>
<tr>
<td>Primary care practitioners role in, 260</td>
<td>Risk factor minimization and prevention in, 259–60</td>
</tr>
<tr>
<td>Cohort studies, 8</td>
<td>Collaborative care, for late-life depression, 247</td>
</tr>
<tr>
<td>Community engagement, in dementia care, 205–6</td>
<td>Community reinforcement approach (CRA), 101</td>
</tr>
<tr>
<td>Community treatment orders (CTOs), 281</td>
<td>Compulsory mental health treatment, 279–82, 286, 289</td>
</tr>
<tr>
<td>Without consent, 286–7</td>
<td>Second opinion safeguards in, 287</td>
</tr>
<tr>
<td>Urgent treatment, 287–8</td>
<td>Computerized tomography (CT) AD, 174</td>
</tr>
<tr>
<td>Other neuroimaging techniques compared with, 175</td>
<td>VaD/VCI, 26, 28–9, 179</td>
</tr>
<tr>
<td>Confidentiality, driving with dementia and, 142, 144</td>
<td>Congophilic angiopathy, 29, 53</td>
</tr>
<tr>
<td>Consent capacity for, 306–7</td>
<td>For home assessment, 131</td>
</tr>
<tr>
<td>Treatment without, 286–7</td>
<td>Consent to treatment provisions, 286–8, 289</td>
</tr>
<tr>
<td>Constipation, in advanced dementia, 231</td>
<td>Constitutive account, 320</td>
</tr>
<tr>
<td>Contingent account, 320</td>
<td>Coroners and Justice Act 2009, 298–9</td>
</tr>
<tr>
<td>Cortical disconnection syndrome, 53</td>
<td>Cortical disconnection, 214</td>
</tr>
<tr>
<td>Corticobasal degeneration, 51</td>
<td>Co-working, in dementia care, 262, 263</td>
</tr>
<tr>
<td>Creatine and, 184, 187</td>
<td>Cross-sectional surveys, 7</td>
</tr>
</tbody>
</table>
Index

333

residence capacity
assessment and, 308–9, 310, 313
delirium tremens, 97
depression. See also late-life depression
dementia with, 8, 12
treatment of, 249–50
VaD/VCI, 32, 33
young-onset, 47
epidemiology of, 13
in PD, 116–18
substance misuse with, 93–4, 98, 106–7
depressive pseudodementia, 186, 250
deprivation of liberty (DoL), 293, 303
‘acid test’ for, 294, 296–7
general hospitals, 298–9
in psychiatric settings, 297
in social care settings, 298
background to concept of, 293–4
Liberty Protection Safeguards, 293
amendments to, 300–3
background to, 299–300
Supreme Court Judgment in P and Q and P in Cheshire West, 294–6
Deprivation of Liberty Safeguards (DoLS), 293–4, 297, 299–300
descriptive epidemiology, 5–6
descriptive studies, 6–7
detention. See civil detention
Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)
bipolar disorder
classification in, 78–9
classification of major
cognitive disorder and minor cognitive disorders in, 154–5
delirium criteria in, 255, 256
dialysis dementia syndrome, 60
diffuse brain damage. See head trauma and diffuse brain damage
diffuse subcortical SVD, 27–30, 53
discharge from civil detention, 288
other routes to, 290
RC/RMO role in, 288
tribunal role in, 288–90
discharge planning, 262
disinhibition syndrome, 79–80
distress behaviours, 224
disulfiram, 99
DLB. See dementia with Lewy bodies
DoL. See deprivation of liberty
doll therapy, 217
DoLS. See Deprivation of Liberty Safeguards
donepezil, 31–3, 46–7
dopamine agonist withdrawal (DAWS), 123
dopamine agonists (DA), ICDs with, 123
dopamine dysregulation syndrome (DDS), 123–4
Down’s syndrome, 185
Driver and Vehicle Licensing Agency (DVLA), 139
driving with dementia guidance, 143–4
driving with dementia, 139, 146–7
ability tests for
in-office testing, 145–6
on-road testing, 144
assessment of risk in, 139
carer reports, 140
clinical presentation, 141
collateral information, 140
comorbidities, 141
self-reports, 140
legislation on
DVLA medical guidance, 143–4
physician reporting requirements, 142
retirement from, 141
available alternative transport impact on, 142
behaviour modification, 141
cessation, 142
Drug Abuse Screening Test (DAST), 109
drug misuse, 105–6, 113
benzodiazepines and
hypnotics, 106–7
cannabis, stimulants, and hallucinogens, 108
diagnostic challenges of, 109, 110
epidemiology of, 16, 106, 107
impacts of, 109, 110
cognition, 111
mental health, 110–11
physical health, 111
inappropriate and over-the-counter medications, 108
opioids and cocaine, 107–8
polysubstance, 108
risk factors for, 106, 107
Toxicity associated with, 62
risk factors for, 106, 107
toxicity associated with, 62
treatment and outcomes of, 111–12
benzodiazepines, 113
opioids, 112–13
DSM-5. See Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
dual syndrome hypothesis, 122
DVLA. See Driver and Vehicle Licensing Agency
eyear-onset dementia. See young-onset dementias
eating disorders, 15
eCAs study. See Epidemiologic Catchment Area study
ECHR. See European Convention on Human Rights and Fundamental Freedoms
electroconvulsive therapy (ECT)
for bipolar disorder, 86–7
compulsory treatment with, 287–8
for late-life depression, 248–9
emergency detention, 283, 284–5
endocrine disorders, dementia caused by, 65
diabetes mellitus, 66
hyperparathyroidism, 64–5
hypoparathyroidism/ hypocalcaemia, 65
hypothyroidism or raised thyroxine, 64
end-of-life care. See palliative care
England and Wales
civil detention in, 282–6, 288–90
consent to treatment provisions in, 286–8, 289
Index

mental health laws of,
279–82, 290–1
environmental
interventions, 218
environments, cognitive-
friendly. See cognitive-
friendly services
Epidemiologic Catchment
Area (ECA) study, 15
epidemiology, 5
conclusions on mental
health in old age, 17
definitions of terms used
in, 5–6
of dementia
AD, 5, 9–10
BDP, 11
comorbid disease, 12
incidence, 7, 8–9
Lewy body dementia, 11
mortality, 12
PDD, 121–3
prevalence, 6–7, 8–9, 39,
50, 73
vascular dementia, 10–11,
24–5, 31
young-onset, 39
of functional illnesses
anxiety-related
disorders, 15
bipolar disorder, 13–14, 80
delirium, 14–15, 254–5
depression, 13
eating disorders, 15
late-onset
schizophrenia, 14
personality disorders,
15–16
substance misuse, 16,
92–3, 106, 107
of mania in late life, 80
observational study designs
used in, 6–8
of suicide in elderly, 16,
17, 18
ecitalopram, 245
ethical aspects
of AD biomarker positivity,
168–9
of alcohol misuse, 95–6
European Convention on
Human Rights and
Fundamental Freedoms
(ECHR), 281, 282,
293–4
exercise therapy, 216–17
falls
alcohol misuse and, 97–8
environmental risk factors
for, 134
familial AD, 50
familial CJD, 55
family members
co-working role for, 207, 208
interview of, 133, 136
family support
for alcohol misuse, 94–5
assessment of, 136
fatal familial insomnia, 55
FDG PET. See fludeoxyglucose
positron emission
tomography
fever, in advanced dementia,
233–4
fludeoxyglucose positron
emission tomography
(FDG PET), dementia
diagnosis with, 173–4
AD, 177–8
AD biomarkers, 167
folate deficiency, 62
Friedreich’s ataxia, 52
frontal lobe dysfunction
bedside tests of, 41, 42
symptoms of, 44
frontotemporal
dementia (FTD) as
degenerative cause of
dementia, 51
driving with, 141
neuroimaging in diagnosis
of, 173–4, 183–4, 187
young-onset, 43–4
behavioural form, 44
language forms, 45
functional approach, to
residence capacity
assessment, 309–11
functional neuroimaging. See
also fludeoxyglucose
positron emission
tomography; positron
emission tomography;
single-photon emission
computed tomography
in AD, 177–8
in DLB, 182–3
in VaD/VCI, 179–80
FX, Re [2017], 311
galantamine, 31–3, 46–7
garden assessment, 135
gastrointestinal system,
alcohol-related damage
of, 97–8
Gaucher disease, 68
general hospitals, DoL ‘acid
test’ in, 298–9
General Medical Council
(GMC), guidance on
confidence and
driving with
dementia, 144
general practitioner (GP),
home assessment
referral by, 130–1
genetics, rare causes of
dementia, 72
Gerstmann–Straussler–
Scheinker disease, 55–6
glucocorticosteroid dementia
syndrome, 61
GMC. See General Medical
Council
GP. See general practitioner
haemochromatosis, 67
Hallervorden–Spatz syndrome.
See pantothenate
kinase-associated
neurodegeneration
hallucinations, in PD, 120–1
hallucinogen misuse, 106, 108
haloperidol, 261–2
head trauma and diffuse brain
damage, dementia
caused by, 59
acute head injury, 63
anoxic brain injury/delayed
post-anoxic
encephalopathy, 63
chronic subdural
haematoma, 64
dementia pugilistica, 63
normal-pressure
hydrocephalus, 63–4
in soccer players, 63
Heart of England NHS
Foundation Trust v JB
[2014], 306–7
heavy metal toxicity, 58–60
Heidegger, Martin, 319–20
Helping Older People
Experience Success
(HOPES), 87–8
hepatic encephalopathy, 66
heroin misuse, 106, 107–8
herpes viruses, 57
Index

pharmacological treatment of age-related physiological changes affecting, 244
combination and augmentation therapy, 246–7
dementia and, 249
monotherapy, 245–6
relapse prevention, 247
response time for, 246
late-onset schizophrenia, 14
lead poisoning, 58–9
legal aspects, of alcohol misuse, 95–6
legislation on driving with dementia
DVLA medical guidance, 143–4
physician reporting requirements, 142
UK mental health laws, 279, 290–1
civil detention, 282–6
compulsory mental health treatment in hospital, 279–82, 286–8, 289
discharge from civil detention, 288–90
overview of, 279–82
Lewy body dementia. See dementia with Lewy bodies
Liberty Protection Safeguards (LPS), 293
amendments to advocacy, 302
age, 300
AMCP role, 301
arrangements, 301
authorization criteria, 301
authorization effect and duration, 302
care home arrangements, 302
consultation, 301
legal appeals, 302
MHA/LPS interface, 303
pre-authorization review, 301
renewals and reviews, 302
statutory definition, 300
background to, 299–300
licence. See driving with dementia
light therapy, 215
likelihood ratios, 30
lithium for bipolar disorder, 85
for late-life depression, 246
as rare cause of dementia, 60
liver disease, substance misuse and, 111
living room assessment, 134–5
‘living well’ with dementia, 191–2
Locke, John, 318
London Borough of Hackney v SJF (through her Litigation Friend the Official Solicitor, JJF [2019]), 313–14
longer-term detention, 283–6
LPS. See Liberty Protection Safeguards
LSD, 108
Lyme disease, 56
magnetic resonance imaging (MRI), 178
AD, 174–7
CJD, 184
other neuroimaging techniques compared with, 175
VaD/VCI, 26, 28–9, 179
major cognitive disorder, DSM-5 classification of, 154–5
major depressive disorder, epidemiology of, 13
major stroke, VaD/VCI after, 26–7
manganese toxicity, 59
mania in late life, 78, 88
aetiology of, 81
burdens of economic, 80–1
morbidty and mortality, 81
suicide, 81
classification of, 78–9
course of, 88
diagnosis and assessment of, 81–3
differential, 82
investigations, 82
screening instruments, 83
epidemiology of, 80
management of, 83–4
non-pharmacological, 86–8
pharmacological, 84–6
prevention of, 88
psychiatric comorbidity with anxiety disorders and substance misuse, 83
cognitive impairment, 83
terms specific to, 79–80
MAOIs. See monoamine oxidase inhibitors
MCA. See Mental Capacity Act 2005
MCI. See mild cognitive impairment
McKhann criteria, 167,
174, 176
medications
home assessment of, 135–6
toxicity associated with, 60–1
memantine, 31–3, 122
for young-onset dementia, 46–7
mental capacity alcohol misuse and, 95–6
UK laws on, 279–82, 306
Mental Capacity Act 2005 (MCA), 95–6, 279, 281
residence capacity and, 306
Mental Capacity (Northern Ireland) Act 2016, 280,
281, 286, 290–1
Mental Capacity (Amendment) Act 2019, 299
mental disorder, MHA definition of, 282
Mental Health Act 1983 (MHA), 95–6, 279, 281,
282, 283, 284–5, 287–8, 289, 290–1
DoL and, 294, 297, 303
Mental Health (Care and Treatment) (Scotland) Act 2003 (MHCTA), 279, 281, 284–5, 289
mental health laws, 279, 290–1
civil detention, 282–6
compulsory mental health treatment in hospital, 279–82, 286–8, 289
discharge from civil detention, 288–90
overview of, 279–82
Mental Health Toolkit, 266
mental illness, 17. See also specific mental illnesses
dementia with, 12
substance misuse with, 110–11
VaD/VCI with, 32
Mental (Northern Ireland) Order 1986 (NI Order),
279, 280, 281,
284–5, 289
mercury poisoning, 59
Merleau-Ponty, Maurice, 320
metabolic disorders, dementia
caused by, 65
adrenoleukodystrophy and adrenomyelo-
neuropathy, 67
cerebral lipidoses –
adult variant, 68
haemochromatosis, 67
metachromatic
leukodystrophy, 67
neuropathy, 67
PKAN, 67–8
Wilson’s disease, 66–7
metachromatic
leukodystrophy, 67
MHA. See Mental Health
Act 1983
MHCTA. See Mental Health
(Care and Treatment)
(Scotland) Act 2003
microinfarcts, 27
mild cognitive impairment
(MCI)
cerebrovascular disease
with, 24
CSF biomarkers for AD
development in, 165–6
definition of, 161, 162
driving with, 141, 144
MMSE in assessment of
for detection of MCI,
152, 153
implementation of, 154–7
for prediction of future
dementia in MCI, 154
neuroimaging in, 173–4,
175, 185
in PD, 121–3
screening for, 149, 150,
154–6, 157
Mini-Mental State
Examination (MMSE), 32, 41
applications of, 150
clinical implementation
of, 154–7
dementia screening
with, 149, 150,
154–6, 157
as diagnostic test for
dementia, 151, 152
early dementia diagnostic
validity of, 151–3
limitations of, 154
MCI detection with, 152, 153
prediction of future
dementia with, 154
structure and validation
of, 150
minor cognitive disorders,
DSM-5
classification of, 154–5
mirtazapine, for late-life
depression, 245, 249
MMSE. See Mini-Mental
State Examination
MND. See motor neuron
disease
MOCA. See Montreal
Cognitive Assessment
monoamine oxidase
inhibitors (MAOIs)
for depression in PD, 118
toxicity associated with, 61
Montreal Cognitive
Assessment (MOCA), 32
mortality
in advanced dementia, 224–6
predictors of, 230–1
alcohol misuse, 92–3
bipolar disorder, 81
dementia and, 12
drug misuse, 109, 110
motor neurone disease
(MND), 52
MRI. See magnetic resonance
imaging
MS. See multiple sclerosis
multi-agency working, for
alcohol misuse, 100–1
multiple sclerosis (MS), 69
multiple system atrophy,
51–2
multisensory stimulation,
216
music therapy, 214–15
Namaste Care, 228–9
Nasu–Hakola disease, 53
National Institute
for Health and Clinical
Excellence (NICE)
bipolar disorder treatment
recommendations, 84
delirium treatment
recommendations, 261–2
dementia treatment
recommendations, 31–3, 46–7
staff training guidance
of, 267–8
young-onset dementia
recommendations, 48
National Institute of
Neurological and
Communicative Disorders
and Stroke and the
Alzheimer’s Disease
and Related Disorders
Association (NINDS–
AIREN), VaD diagnostic
criteria of, 167, 174, 176
National Institute of
Neurological Disorders
and Stroke and the
Alzheimer’s Disease
and Related Disorders
Association (NINCDS–
ADRDA), AD diagnostic
criteria of, 178, 179
National Institute on Aging
and the Alzheimer’s
Association (NIA–AA),
AD diagnostic
criteria of, 167–8
needs-driven behaviours,
224
neighbourhood,
assessment of, 133
neoplasm, dementia
caused by, 65, 68–9
neuropathy, 67
neuroacanthocytosis, 68
neurocysticercosis, 57
neurodegeneration,
in AD, 162–3
biomarkers of, 164–5
neurofibillary tangles,
in AD, 162–3
biomarkers of, 164–5
neurofilament light chain (NfL), 164
neuroimaging in dementia, 173–4, 186
AD, 173–8, 186–7
AD biomarkers, 164–5, 167, 178
CJD, 184, 187
depressive pseudodementia, 186
DLB, 173–4, 180–3, 187
FTD, 173–4, 183–4, 187
Huntington’s disease, 184, 187
MCI, 173–4, 175, 185
in people with intellectual disability, 185
progressive supranuclear palsy, 184
recommendations for, 187–8
technique comparison, 175
VaD/VCI, 26–9, 32, 178–80, 187
young-onset dementias, 41–2, 185–6
neuropsychological testing
VaD/VCI, 32
young-onset dementias, 41, 42
neuroarcsisoides, 70
neurostimulation, for late-life depression, 248–9
neurosylphusis, 56–7
NfL. See neurofilmament light chain
NI Order. See Mental Health and Clinical Excellence
NIA-AA. See National Institute on Aging and the Alzheimer’s Association
niacin deficiency, 62
NICE. See National Institute for Health and Clinical Excellence
Niemann–Pick disease, 68
NINCDS-ADRDA. See National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association
NINDS–AIREN. See National Institute of Neurological Disorders and Stroke and Association Internationale pour le Recherché et l’Enseignement en Neurosciences
NM-ASSIST, 109
non-maleficence, AD biomarker
Northern Ireland civil detention in, 282–6
mental health laws of, 288
mental health laws of,
8, 186–289
8, 290–1
279–82
290–1
nortriptyline, for late-life depression, 246
nutrition, in advanced dementia, 234
observational studies, 5, 6
case-control studies, 7–8
cohort studies, 8
cross-sectional surveys, 7
descriptive studies, 6–7
ocular biomarkers, of AD, 165
odds ratio, 7–8
olanzapine, 86, 246–7
on-road testing, 144
opioid misuse, 106, 107–8
polysubstance misuse with, 108
treatment and outcomes of, 112–13
organ failure, dementia caused by, 65
hepatic encephalopathy, 66
renal encephalopathy, 66
organophosphate exposure, 60
Ottawa Driving and Dementia Toolkit, 145
over-the-counter medication misuse, 108
pain, in advanced dementia, 231–3
palliative care in dementia, 223, 236–7
ACP in, 236
artificial nutrition and hydration in, 234
components, domains, and key factors of, 227–8
definition of, 223
effectiveness of, 226, 228–30
infection and fever considerations, 233–4
need for improvement of, 224–6, 236–7
pain considerations, 231–3
physical health considerations, 231
prediction of death in, 230–1
resuscitation in, 235
spectrum of, 224
spiritual and religious needs in, 235–6
symptoms to address in, 224–6
Palliative Excellence in Alzheimer Care Efforts (PEACE), 226
pantothenate kinase-associated neurodegeneration (PKAN), 67
paraneoplastic disorder, 65, 68–9
Parfit, Derek, 318
Parkinson’s disease (PD), neuropsychiatric symptoms of, 116, 117, 124
anxiety, 119–20
apathy, 118–19
cognitive impairment, 45, 121–3
delirium, 123
depression, 116–18
psychosis, 120–1
treatment related disorders, 123–4
Parkinson’s disease dementia (PDD), 45, 121–3
PC & NC v City of York Council [2013], 307–8
PCC. See person-centred care
PD. See Parkinson’s disease
Index

340

PDD. See Parkinson's disease dementia
PEACE. See Palliative Excellence in Alzheimer Care Efforts
peer support, in dementia care, 208
pellagra, 62
period prevalence, 6
periventricular white matter lesions, 179
personality disorders, 15–16
person-centred care (PCC), 202, 210–11
challenges to practice of, 209
cultural shift, 210
hope maintenance, 209
transformation of risk management to safety planning, 209–10
conceptual underpinning to, 317–18, 324–5
definition of recovery and, 202–3
RFP key aspects for co-working opportunities, 207, 208
issues of identity, 205
need for inclusion, 205–6
peer support, 208
self-management empowerment, 208–9
RFP parallels with, 203–5
personhood, 206
clinico-philosophical case discussion of, 317–18, 325
case vignette of SEA view in practice, 320–4
discussion, 324–5
interventions and, 323–4
SEA view, 318–20
therapeutic engagement and, 324
pesticide exposure, 60
PET. See positron emission tomography
phosphorylated tau (p-tau), in AD, 164, 165–6
physical health in advanced dementia, 231
substance misuse impacts on, 111
physician reporting, of driving with dementia, 142
pimavanserin, 121
PKAN. See pantothenate kinase-associated neurodegeneration plasma, AD biomarkers in, 164
pneumonia, in advanced dementia, 233–4
POCD. See Post-Operative Cognitive Disorder
point prevalence, 6
polycystic lipomembranous osteodysplasia with sclerosis (PLOMOS), 53
polysubstance misuse, 108
positron emission tomography (PET), 173–4
AD, 177–8
AD biomarkers on, 164–5, 167, 178
DLB, 182–3
other neuroimaging techniques compared with, 175
VaD/VCI, 179–80
post-anoxic encephalopathy, 63
post-hospitalization management, for delirium, 262
Post-Operative Cognitive Disorder (POCD), 255–6
pramipexole, 118
preclinical AD, 161, 162.
See also AD biomarkers
prescribed medication misuse, 108
prevalence, 5, 6
of dementia, 6–7, 8–9, 39, 50, 73
PRIDE study. See Prolonging Remission in the Depressed Elderly study
primary progressive aphasia, 45
prion diseases. See human prion diseases
prisoners, with dementia, 237
problem-solving therapy (PST), 247–8
prodromal AD, 161, 162
progressive supranuclear palsy, neuroimaging in diagnosis of, 184
Prolonging Remission in the Depressed Elderly (PRIDE) study, 248–9
PST. See problem-solving therapy
psychoeducation, for bipolar disorder, 87
psychological interventions for dementia cognitive interventions, 217–18
doll therapy, 217
for late-life depression, 247–8
dementia with, 249
psychosis, in PD, 120–1
psychosocial interventions for alcohol misuse, 94, 95
for bipolar disorder, 87–8
for dementia, 213–14, 219
activity based, 216–17
carer-focused, 218
creative, 214–15
environmental, 218
psychological, 217–18
sensory, 215–16
for late-life depression, 248, 249
psychotherapy for bipolar disorder, 87
for young-onset dementias, 47
p-tau. See phosphorylated tau
pimavanserin, 121
quetiapine, 121
punch drunk syndrome, 63
pure hippocampal sclerosis (ageing subtype), 50–1
quality of life, 17
RBP. See Responsible Bodies
RC. See responsible clinician
RDB. See Kookwood Driving Battery
recovery definition of, 192, 202–3
self-management in dementia and, 192–3
Short Michigan Alcoholism Screening Test – Geriatric version (SMAST-G), 94
short-term detention, 283–6
short-term integrated palliative and supportive care (SIPS) model, 229
Shy–Drager syndrome, 51–2
single-photon emission computed tomography (SPECT), 173–4
AD, 177
DLB, 182–3
other neuroimaging techniques compared with, 175
VaD/VCI, 179–80
SIPS model. See short-term integrated palliative and supportive care model
treated embodied agent (SEA), view of person as, 318–20
case vignette, 320–4
discussion, 324–5
interventions and, 323–4
therapeutic engagement and, 324
understanding of patients through, 321–2
Sjögren syndrome, 71
small vessel disease (SVD), VaD/VCI after, 27–30, 53
SMAST-G. See Short Michigan Alcoholism Screening Test – Geriatric version
soccer, dementia and, 63
Social Care Institute for Excellence, young-onset dementia recommendations, 48
social care settings, DoL 'acid test' in, 298
social exclusion, in dementia, 205–6
soluble platelet-derived growth factor receptor β (sPDGFRβ), 164
SPECT. See single-photon emission computed tomography
spinocerebellar ataxias, 52
spiritual needs, in advanced dementia, 235–6
sporadic CJD, 54
SSCS model. See Stress-Strain-Coping-Support model
SSRIs. See selective serotonin reuptake inhibitors
stains, for VaD/VCI, 33
steroids, toxicity associated with, 61
STI. See Serial Trial Intervention
stimulant misuse, 108
Stress-Strain-Coping-Support (SSCS) model, 94–5
stroke, VaD/VCI after, 26–7, 28
subacute sclerosis panencephalitis, 58
subdural haematoma, 64
substance misuse. See also alcohol misuse; drug misuse
bipolar disorder comorbidity with, 83
epidemiology of, 16, 92–3, 106, 107
mental illness with, 110–11
toxicity associated with, 62
suicide
alcohol misuse and, 98
bipolar disorder and, 81
epidemiology of, 16, 17, 18
Supreme Court Judgment in P and Q and P in Cheshire West, 294–9
residence capacity and, 308
SVD. See small vessel disease
Sydney Multicenter Study, 122
syphilis, 56–7
systemic lupus erythematosus, 71
systemic vasculitis, 70
tau proteins, in AD at different disease stages, 166
measurement of, 164–5
pathophysiology, 162–3
predictive accuracy of, 165–6
Taylor, Charles, 319
Tay–Sachs disease, 68
TCAs. See tricyclic antidepressants
telephone contact, for home assessment, 131
therapeutic engagement, 324
thiamine deficiency, 97
thyroxine, high levels of, 64
TMS. See transcranial magnetic stimulation
total tau (t-tau), in AD, 164, 165–6
toxicity, dementia caused by, 59
alcohol and recreational drugs, 62
heavy metals, 58
organophosphates toxicity associated with, 62
thyroxine, high levels of, 64
transcranial magnetic stimulation (TMS), for late-life depression, 249
treatment without consent, 286–7
tribunals, for discharge from civil detention, 288–90
tricyclic antidepressants (TCAs) for depression in PD, 118
for late-life depression, 246
mania induced by, 79
toxicity associated with, 61
t-tau. See total tau
tube feeding, in advanced dementia, 234
United Kingdom mental health laws. See mental health laws
urgent treatment, compulsory, 287–8
VaD/VCI. See vascular dementia/vascular cognitive impairment
valproate, 85–6
variant CJD (vCJD), 55, 184
vascular dementia/vascular
cognitive impairment
(VaD/VCI), 24–6, 33–4
AD compared with, 30–1
AD mixed with, 24–5, 26
clinical assessment of, 31, 32
diagnostic criteria for, 30–1, 178, 179
epidemiology of, 10–11, 24–7
neuroimaging in
diagnosis of, 26–9, 32, 178, 179, 187
functional, 179–80
periventricular white
matter lesions, 179
pathology, 25–6
CAA, 29, 53
diffuse subcortical SVD, 27–30, 53
lacunar stroke, 27, 28
major stroke, 26–7
mechanism
underlying, 29–30
microinfarcts, 27
mixed or multiple
forms of, 24–5, 26, 29
neuroradiology
and, 26–9, 32
rare causes of, 53–4
treatment of
cognitive changes, 31–3
control of vascular
risk factors, 33
symptomatic, 33
young-onset, 43
vascular depression, 250
vascular mania, 80
vasculitis, 70
cerebrovascular disease
(CD), 29
vCJD. See variant CJD
differential diagnosis of, 40
clinical approach to assessment for, 40
further investigations, 41–2
history, 40
physical examination, 41
management of, 46
psychological and
non-pharmacological
interventions, 47
national recommendations for, 48
neuroimaging in, 41–2, 185–6
prevalence of, 39
services for, 38, 47–8
Ziprasidone, 261–2
Zopiclone, 106
young-onset dementias
causes of, 43
AD, 43
alcohol-related
dementia, 45
DLB, 45
FTDs, 43–5
Huntington’s and
other rarer causes, 45–6
VaD/VCI, 43
definition of, 38
dementias in later
life in later life
compared with, 38–9
diagnosis of clinical approach to assessment for, 40
cognitive testing, 41, 42
differential, 40
distribution of, 39–40
further investigations, 41–2
history, 40
physical examination, 41
management of, 46
pharmacological
interventions, 46–7
psychological and
non-pharmacological
interventions, 47
national recommendations for, 48
neuroimaging in, 41–2, 185–6
prevalence of, 39
services for, 38, 47–8